A novel fibrinogen variant (fibrinogen Seoul II; A慣Gln328Pro) characterized by impaired fibrin 慣-chain cross-linking by 理쒖쥌�씫 & �넚寃쎌닚
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
A novel fibrinogen variant (fibrinogen Seoul II; AGln328Pro) characterized by
impaired fibrin -chain cross-linking
Rojin Park, Hyun-Ju Doh, Seong-Soo A. An, Jong-Rak Choi, Kwang-Hoe Chung, and Kyung-Soon Song
We report a novel fibrinogen variant (fi-
brinogen Seoul II), which has a heterozy-
gous point mutation from CAA to CCA
leading to AGln328Pro. The mutation
site is among several glutamine residues
that serve as-chain cross-linking accep-
tor sites. Fibrinogen Seoul II was found in
a 51-year-old male patient and his family
in Seoul, Korea. The patient was diag-
nosed with myocardial infarction at age
43. Eight years later he was admitted to
the emergency room due to recurrence of
the disease, where he expired under treat-
ment with tissue plasminogen activator
(t-PA). Fibrin polymerization curves, made
using purified fibrinogen from the pa-
tient’s relatives, showed a decreased fi-
nal turbidity, suggesting Seoul II fibrin
clots are composed of thinner fibers. This
supposition was verified using scanning
electron microscopy. Alpha-polymer for-
mation by the mutant fibrinogen upon
thrombin treatment in the presence of
factor XIII and calcium was distinctly
impaired. This result confirms that the
residue A328 plays a pivotal role in
-chain cross-linking. (Blood. 2006;108:
1919-1924)
© 2006 by The American Society of Hematology
Introduction
Fibrinogen, one of the critical plasma proteins, is a 340-kDa
glycoprotein1 synthesized in the liver2,3 and has essential roles in
both blood coagulation and platelet aggregation.4 Fibrinogen is a
dimer consisting of 2 identical pairs of A, B, and  chains
intertwined to form a trinodular molecule with 2 terminal D regions
and a central E region.5,6 The D region includes the carboxyl
termini of the B and  chains, while that of the A chain goes
beyond the D region to form the C domain, which is composed
of residues A220-6107 and normally interacts with the central
E region.
In the process of blood coagulation, thrombin cleaves fibrinopep-
tides A and B from A and B chains to form a fibrin monomer,
exposing the GPR and GHRP sequences, respectively. Subse-
quently, protofibrils in a half-staggered array are formed, and the
release of C domains from the central E region is facilitated,
allowing lateral aggregations through intermolecular associations
between C domains.8,9 The final phase of fibrin clot formation
involves the covalent modification of fibrin molecules by factor
XIIIa. The factor XIIIa–mediated cross-linking process, where -
cross-linking follows - cross-linking, contributes to stabilization
of the fibrin clot and resistance to thrombolytic agents.10,11 Until
now, a variety of mutations in each of the fibrinogen chain genes
have been reported in more than 350 families all over the world,
with A-chain mutation as the most common form.12 Those
mutations usually have been associated with dysfibrinogenemia or
hypofibrinogenemia, both of which feature decreased levels of
plasma fibrinogen activity. Each A-chain has at least 2 glutamine
acceptor sites located at amino acid residues 328 and 366 and 5
potential lysine donor sites between residues 518 and 584.13 A
glutamine 328 is among several glutamine residues that serve as
-chain cross-linking acceptor sites,10 for which only one fibrino-
gen variant has been described: compound heterozygotes character-
ized by a stop mutation at AGln328 resulting in truncation of the
A-chain (Fibrinogen Keokuk14).
Here we present a novel fibrinogen variant (fibrinogen Seoul II),
which has a heterozygous point mutation from CAA to CCA,
resulting in a glutamine-to-proline substitution at residue 328 in the
carboxyl-terminal region of the fibrinogen A-chain. We investi-
gated how this mutation impacted fibrin polymerization and
cross-linking through various in vitro tests on purified fibrinogens
from the index subject and his family members.
Patients, materials, and methods
Patients studied
Fibrinogen Seoul II was found in a 51-year-old male patient with
myocardial infarction and his 8-year-old son and 79-year-old mother. The
patient’s illness was diagnosed as myocardial infarction at age 43. Eight
years later he was admitted to the emergency room, where he expired during
treatment with tissue plasminogen activator (t-PA). The patient’s son and
mother also were enrolled in this study to evaluate possible functional or
structural defects of fibrinogen in his family. Only the subject received t-PA
treatment. All participants or their representatives gave informed consent.
Sample collection and preparation
Blood was collected into 0.109 M trisodium citrate tubes by venipuncture.
The patient’s plasma was collected under the conditions of t-PA treatment,
and his relatives were in normal condition. Platelet-poor plasma was
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prepared by centrifugation for 15 minutes at 2300g and stored at 70°C.
Blood for DNA analysis was collected into 15% K3 EDTA (ethylenediami-
netetraacetic acid) tubes. Genomic DNA was isolated from white blood
cells as previously described15 and also stored at 70°C.
Coagulation tests
Prepared plasma was used to measure plasma fibrinogen activity based on
the Clauss method16 using an STA coagulation analyzer and reagent kit
(Diagnostica Stago, Asniers, France). Plasma fibrinogen antigen level was
measured by the immunologic method using a nephelometer and antiserum
(Dade-Behring, Deerfield, IL) if needed. Thrombin time was measured
using the STA coagulation analyzer and reagent kit.
DNA sequence analysis
Primers were designed for all exons, exon-intron boundaries, and promoter
regions of the fibrinogen A (FGA, GenBank M64982), B (FGB,
GenBank M64983), and  (FGG, GenBank M10014) chain genes. These
genes were amplified from genomic DNA using standard polymerase chain
reaction (PCR) protocols.17 The point mutation causing fibrinogen Seoul II,
located in exon 5 of the fibrinogen A-chain, was amplified using the
primers 5GACTGCAACCTGGAAACCTG3 (forward) and 5TGGTTGT-
GCTACCAGAGGTG3 (reverse). PCR products were purified using the
QIAquick PCR purification kit (QIAGEN, Valencia, CA) and sequenced
using a Dye Terminator Cycle Sequencing Ready Reaction Kit with
AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA) and an
ABI 3700 sequencer (Applied Biosystems) following the protocols sup-
plied by the manufacturer.
Fibrinogen purification
Plasma samples from subjects with and without the molecular defect were
fractionated using gel filtration chromatography on Hiload 16/60 superdex
200 columns (Amersham Biosciences, Piscataway, NJ) equilibrated with 10
mM sodium phosphate, pH 7.4, 0.5 M NaCl buffer. The first peak among 3
main peaks, which included fibrinogen, was pooled and precipitated with
22.5% ammonium sulfate solution for 30 minutes at 4°C in ice followed by
centrifugation at 14 000g for 20 minutes. The pellet was washed twice with
25% ammonium sulfate solution, resuspended in 20 mM Hepes (N-2
hydroxyethylpiperazine-N-2ethanesulfonic acid) buffer, pH 7.4, 150 mM
NaCl, and dialyzed against the same buffer overnight at 4°C. The protein
concentration was determined by the BCA (bicinchoninic acid) method
using a BCA protein assay kit (Pierce Biotechnology, Rockford, IL).
Fibrinogen purity was assessed by separation on 4% to 20% gradient
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) gel.
Thrombin-catalyzed fibrin polymerization
Purified fibrinogen in 20 mM Hepes buffer, pH 7.4, 150 mM NaCl, was
used to perform fibrin polymerization tests. Fibrinogen concentration was
adjusted to 0.15 mg/mL with 50 mM TBS (tris[hydroxymethyl]aminometh-
ane–buffered saline), 150 mM NaCl, pH 7.4 buffer. Fibrin polymerization
for normal and heterozygous Seoul II fibrinogen from the patient’s son was
initiated by adding 1 L of 20 National Institutes of Health (NIH) unit/mL
thrombin (final concentration, 0.1 NIH unit/mL, HYPHEN BioMed,
Andresy, France) to the purified fibrinogens. Change in optical density at
350 nm was monitored at 30-second intervals for 60 minutes at room
temperature in a SpectraMax Plus 384 (Molecular Devices, Union City,
CA). All experiments were performed 3 times.
Fibrinogen clottability
Clottability of the purified fibrinogens was determined essentially as
previously described.18 Purified fibrinogen in 20 mM Hepes buffer, pH 7.4,
150 mM NaCl, was used for clottability testing. The fibrinogen concentra-
tion was adjusted to 0.45 mg/mL with 50 mM TBS, 150 mM NaCl, pH 7.4,
and 1 mM CaCl2. Human -thrombin (final concentration, 0.1 U/mL) was
added for clottability of normal and heterozygous Seoul II fibrinogen.
Samples were incubated for 3 hours at 37°C, followed by an overnight
incubation at 4°C. The reaction was terminated by centrifugation at 2300g
for 20 minutes. The fibrin(ogen) that was not incorporated into the fibrin gel
was determined from the A280 of the supernatant, and the ability to clot was
calculated as (A280 at zero time  A280 of the supernatant)/(A280 at zero
time)  100%.
SDS-PAGE analysis of factor XIIIa–catalyzed cross-linking
of fibrin
Formation of -dimer and -polymer upon thrombin treatment in the
presence of FXIII and 2.5 mM calcium chloride was analyzed using
SDS-PAGE. Purified fibrinogen concentration was adjusted to 0.8 mg/mL
in 20 mM Hepes buffer, pH 7.4, 150 mM NaCl, and incubated in distilled
water containing 1 NIH unit/mL thrombin (HYPHEN BioMed) in the
presence of 1 U/mL factor XIII (Merck Biosciences, Darmstadt, Germany)
and 2.5 mM calcium. SDS was added after incubation times of 0, 1, 2, 5, 10,
and 30 minutes to stop the clotting reaction. Boiling in a reducing
SDS-PAGE solution immediately dissolved each clot. The extent of -chain
cross-linking for heterozygous Seoul II and normal fibrin clots was assessed
by SDS-PAGE. Densitometry of -monomer bands was carried out using
Gelscope 1.5 software (Biobud Co, Ltd, Seoul, Korea).
t-PA–mediated plasmin digestion on fibrin (fibrinolysis profile)
To analyze the profile of t-PA–mediated plasmin degradation, purified
fibrinogen (0.2 mg/mL) was mixed with tPA (Sigma-Aldrich, St Louis,
MO) (27.4 ng/mL, about 0.25 U/mL), plasminogen (10 g/mL) (HYPHEN
BioMed), and FXIII (from 2% fresh human plasma) in 50 mM TBS
containing 5 mM CaCl2. 0.2 U/mL of thrombin was added, and the turbidity
of polymerizing or digesting fibrin at 350 nm was monitored every 20
seconds for 65 minutes using a SpectraMax Plus-384 plate reader (Molecu-
lar Devices) at 37°C. All experiments were performed 3 times.
Scanning electron microscopy and measurement of fiber
diameter and branch point number
To investigate the structure of Seoul II fibrin clots, thrombin (1 NIH
unit/mL, HYPHEN BioMed), CaCl2 (final concentration, 5 mM), and factor
XIII (final concentration, 10 g/mL) were added to purified fibrinogen
(final concentration, 1 mg/mL) from the subject’s relatives. After a
90-minute incubation in a moist environment, the resulting clots were
processed for scanning electron microscopy by fixation, dehydration,
critical point drying, and coating as described previously.19 Clots were
observed and photographed digitally in at least 2 different areas per clot,
using a scanning electron microscope (S-800, Hitachi, Tokyo, Japan). Fiber
thickness and branch point number per square micrometer were measured
using MediScreen 1.0 software (Biobud). Statistical analyses were per-
formed by means of SPSS 11.0 for Windows (SPSS, Chicago, IL). One-way
analysis of variance (ANOVA) followed by Scheffe´ and Tukey tests was
used to compare fiber thickness.
Results
Study of the index case
Coagulation tests in the emergency room for the index subject
showed plasma fibrinogen activity of less than 1.32 M (45
mg/dL), but fibrinogen antigen levels of 6.68 M (227 mg/dL;
within normal range). This discrepant result prompted the investi-
gation of the possibility of hereditary dysfibrinogenemia, as the
subject had no other risk factors for dysfibrinogenemia except for
the t-PA treatment in the emergency room. The patient showed
markedly prolonged prothrombin time (PT, 29.5 seconds; reference
range, 11-15 seconds), activated partial thromboplastin time (aPTT,
180 seconds; reference range, 29-45 seconds), and thrombin time
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( 240 seconds). DNA sequencing of all exons and their bound-
aries of the fibrinogen A, B, and  chains revealed the presence
of Seoul II fibrinogen (Figure 1). SDS-PAGE on purified fibrinogen
from the subject showed the presence of various sizes of fragments
considered to have originated from fibrinogen (Figure 2). In
addition, thrombin-catalyzed polymerization of fibrin from the
subject was markedly impaired, compared with that of normal
fibrinogen (data not shown). N-terminal sequencing was performed
on the various SDS-PAGE fragments, demonstrating that -chain
fragments of 24 kDa and 26 kDa and -chain fragments of 38 kDa
and 50 kDa were formed by plasmin activated from plasminogen
by t-PA (Figure 2).
Coagulation tests
Coagulation studies of the subject’s family members showed that
PT and aPTT were within normal ranges. In both the subject’s son
and mother, plasma fibrinogen activities were 8.23 M (280
mg/dL) and 10.06 M (342 mg/dL), respectively, and thrombin
times were 17.9 seconds and 16.5 seconds, respectively. These
results were all within normal range.
DNA sequencing result
DNA sequencing of fibrinogen genes from the subject and his
family members revealed that all 3 had a point mutation changing
the triplet CAA coding for AGln328 to CCA, resulting in
substitution of glutamine (Gln) to proline (Pro). As shown in Figure
1, both adenine and guanine were found at position 4315 in the
DNA sequencing of exon 5 derived from the A-chain genes of the
subject and his relatives, indicating a heterozygous mutation.
No other mutations were found in the full sequences of all exons
and exon-intron boundaries of the A, B, and  chains from
this family.
Thrombin-catalyzed fibrin polymerization and
fibrinogen clottability
Although family member fibrinogen concentration was normal,
fibrin polymerization of heterozygous Seoul II fibrinogen from the
subject’s son, as monitored by turbidity at 350 nm at room
temperature, showed a decreased final turbidity compared to that of
the normal fibrinogen (Figure 3). The kinetic curve for the turbidity
of fibrin polymerization revealed that heterozygous Seoul II fibrin
polymerization had a lag phase of 240 seconds, a Vmax of
0.53  104 U/s, and a final turbidity of 0.040 U compared with the
control values of 150 seconds, 1.04  104 U/s, and 0.064 U,
respectively. Fibrin(ogen) clottability was 98% and 97% in normal
and heterozygous Seoul II fibrin(ogen), respectively.
SDS-PAGE analysis of factor XIIIa–induced fibrin cross-linking
Time-interval SDS-PAGE analysis of fibrin cross-linking induced
by factor XIIIa demonstrated that more -monomers remained in
Figure 4. SDS-PAGE analysis of factor XIIIa–catalyzed cross-linking of fibrin.
SDS-PAGE analysis of -dimer and -polymer formation upon thrombin treatment in
the presence of factor XIII and calcium in heterozygous Seoul II fibrinogen (right) and
normal control. Incubation with thrombin for 0, 1, 2, 5, 10, and 30 minutes formed
clots, respectively. More A-chain bands remain for the heterozygous Seoul II fibrin
clot (arrow) after 30 minutes of reaction time compared to the normal control,
suggesting that A-chain cross-linking is impaired by Seoul II mutation. Standard
(Std) size equals 250, 150, 100, 75, 50, 37, 25, 15, and 10 kDa from top to bottom,
respectively.
Figure 1. DNA sequencing. DNA sequence analysis of exon 5 of the A-chain gene
in Seoul II mutation and normal control. Seoul II is shown to have a heterozygous
point mutation, with the conversion of CAA to CCA resulting in Gln to Pro substitution
at A residue 328.
Figure 2. SDS-PAGE of reduced fibrinogen from index subject (I) and normal
control (N). A- or B-chain fragments were identified through N-terminal sequenc-
ing. Intact A- or B-chain bands are seen in the normal control, but not the index
subject. N-terminal sequence of each band is as follows: 24 kDa, ADSGEGDFLA; 25
kDa, ADSGEGDFLA; 38 kDa, DNENVVNEYS; 50 kDa, ARPAKAAATQ.
Figure 3. Thrombin-catalyzed fibrin polymerization curve. Thrombin-catalyzed
fibrin polymerization curve of heterozygous Seoul II fibrinogen (dotted) and normal
control (solid). The final turbidity of heterozygous Seoul II fibrin clots was moderately
decreased compared to the normal control.
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the heterozygous Seoul II fibrin clot after 30 minutes of reaction
time than in normal fibrin clots (Figure 4), suggesting incomplete
cross-link formation. Densitometry studies showed that approxi-
mately 41% of heterozygous Seoul II -monomer was cross-linked
by FXIII, as compared to 80% of normal -monomer after 30
minutes’ reaction time. On the contrary, -chain cross-linking of
heterozygous Seoul II fibrin was accelerated in 1 to 5 minutes when
treated with factor XIIIa, compared to that of normal fibrin.
t-PA–mediated plasmin digestion of fibrin (fibrinolysis profile)
Differences between fibrin polymerization to fibrinolysis catalyzed
by plasmin activated from plasminogen by t-PA for normal and
heterozygous Seoul II fibrinogen are shown in Figure 5. Baseline
absorbance was established using only normal fibrinogen without
thrombin activity. Peak absorbance, where fibrinolysis begins to
exceed polymerization, came 40 seconds later in heterozygous
Seoul II fibrin than in normal fibrin. As with the thrombin-
induced fibrin polymerization curve (Figure 3), the difference in
peak turbidity between normal and heterozygous Seoul II fibrin
clot was evident.
Scanning electron microscopy of fibrin clots
Fiber thickness differed significantly between normal and heterozy-
gous Seoul II fibrin clots, based on diameter measurements using
scanning electron microscopy (Table 1). Heterozygous Seoul II
fibrin clots showed thinner fibers than normal fibrin clots (Figure
6). This result corresponds with the observation that final turbidity
of thrombin-catalyzed fibrin polymerization was lower in heterozy-
gous Seoul II fibrin than in normal fibrin. The subject’s mother and
son had similar fiber thickness by scanning electron microscopy.
There was no significant difference in branch point number per
square micrometer between normal and heterozygous Seoul II
fibrin clots (Table 2).
Discussion
Dysfibrinogenemia was suggested in the index subject, according
to emergency room measurements of initial plasma fibrinogen
activity and antigen. In addition, DNA sequence analysis showed
hereditary dysfibrinogenemia. However, we conclude that the
abnormal coagulation profile of the patient, including plasma
fibrinogen activity level, resulted from his treatment with t-PA. A
study of 3 generations demonstrated that the subject’s mother and
the only son also shared the same mutation. They were shown to
have normal plasma fibrinogen activities. Fibrin polymerization
curve revealed low turbidity (data not shown) in the index subject,
which was considered exaggerated when taking a heterozygous
mutation into account. More information was elucidated by
reducing SDS-PAGE of purified fibrinogen showing various sizes
of bands derived from fibrinogen. N-terminal sequencing proved
that these are - or -chain fragments (Figure 2). This finding was
supported by the fact that the patient received a large amount of
t-PA in the emergency room. To further understand the characteris-
tics of fibrinogen Seoul II, purified fibrinogens from the subject’s
8-year-old son and 79-year-old mother also were closely examined.
AGlu328, located in the C-domain, is composed of residues
A220-6107 and is one of the places where isopeptide -glutamyl-
	-lysyl bond forms when fibrin assembly is followed by cross-
linking induced by factor XIIIa.10,13,20 Two C-domains interact
with the central portion of the molecule, from which they dissociate
and become available for intermolecular interaction when fibrin
assembly takes place.8,9 These intermolecular interactions between
C-domains are important for the enhancement of lateral aggrega-
tion during fibrin polymerization.7 Therefore, C-domains are
thought to play a major role in fibrin polymerization and stabiliza-
tion through covalent -cross-linking. Approximately 22 C-
domain mutations have been described. Sixteen mutations cause
Figure 5. Fibrinolysis profile of purified fibrinogen. Peak absorbance came 40
seconds later in heterozygous Seoul II than in normal clots. The subject’s mother
(Seoul II.2) and son (Seoul II.3), who also have Seoul II fibrinogen, showed similar
absorbance changes.
Table 1. Measurement of fibrin fiber diameter
No. of fibers Mean, nm SD
Normal 307 133 20
Son (heterozygous Seoul II) 307 105* 21
Mother (heterozygous Seoul II) 307 109* 21
*Significant differences (P 
 .01) between normal fibrin and heterozygous Seoul
II fibrins (ANOVA with Scheffe´ and Tukey post hoc analysis).
Figure 6. Scanning electron microscopy of fibrin clots. Scanning electron
microscopy images of heterozygous Seoul II fibrin clots (right) and normal fibrin clots
(left) are shown. Heterozygous Seoul II fibrin clot showed thinner fibers than normal
control (bar equals 3 m).
Table 2. Measurement of branch point number
No. of m2
counted
Mean branch point
number per m2 SD
Normal 350 1.39 0.74
Son (heterozygous Seoul II) 344 1.45* 0.73
Mother (heterozygous Seoul II) 346 1.36* 0.70
*No significant differences (P  .05) between normal fibrin and heterozygous
Seoul II fibrins (ANOVA).
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dysfibrinogenemia characterized by prematurely truncated A-
chains due to nonsense or frame-shift mutations, including Otago,
Switzerland B6,21 Turkey B5,21 France A7,22 France A12,22 Keo-
kuk, United States B3,22 Milano III, Nieuwegein, Marburg, Caracas
I, Lincoln, Perth, San Giovanni Rotondo, Paris VII, and Indianapo-
lis IV. One mutation (Champagne Au Mont d’Or) is an insertion of
39 amino acids. The other 5 are missense mutations; Caracas II is
an N-glycosylated Asn substitution, Indianapolis and Indianapolis
II are associated with renal amyloidosis, and Caracas V and
Dusart/Paris V are related to fibrinogen-albumin complex forma-
tion. As a missense mutation of the C-domain, fibrinogen Seoul II
is unique because it is related to the -chain cross-linking site.
Until now, the recently reported fibrinogen variant Keokuk14
has been the only described cross-linking site mutation. This
compound heterozygous mutation of AGln328stop and
AIVS4  1G3 T results in truncated fibrinogen formation,
leading to impaired polymerization and -cross-linking. In con-
trast, the Seoul II mutation causes an amino acid substitution
(AGln328Pro) but does not form a stop codon.
In characterizing heterozygous Seoul II fibrinogen, 2 findings
were of particular interest. First, polymerization curves for the
clotting of purified heterozygous Seoul II fibrinogen showed
approximately two thirds of final clot turbidity compared with that
of normal fibrinogen. The mechanism by which the mutation
affects the final polymerization turbidity is uncertain. One possibil-
ity is that the substitution of proline for glutamine at residue A328
may alter the tertiary structure of the C domain, leading to a turn
in the polypeptide chain and impairing intermolecular interactions
(lateral aggregation). In general, the replacement of an amino acid
with proline has been known to give rise to conformational change
of proteins through the distortion of the regular helical structure
and loss of a backbone hydrogen bond.23-27 Scanning electron
microscopic observations of thinner fibers in the heterozygous
Seoul II fibrin clots (Figure 6) seem to support this idea. Although
clots prepared for scanning electron microscopy were treated
with FXIIIa, this reaction did not seem to substantially affect
clot morphology, except for making fibrin fibers a little thinner
and longer.10,28
Second, when heterozygous Seoul II fibrin clots were formed by
incubation with thrombin and FXIIIa (Figure 4), incomplete
-chain cross-link formation was shown, as demonstrated by
reducing SDS-PAGE analysis. Approximately 41% of heterozy-
gous Seoul II -monomer was cross-linked by FXIIIa, as compared
to 80% of normal -monomer after 30 minutes’ reaction time. This
finding indicates that the residue A328 plays an important role in
-chain cross-linking and that the AGln328Pro mutation prevents
FXIIIa from functioning as an active transglutaminase between
glutamine and lysine to stabilize fibrin clots. So far, several
glutamine residues, such as AGln 221,29 237,29 328,20,29 and
36620, are known to be involved in the -chain cross-linking
reaction. Recently, a C-terminal portion of the C-domain, includ-
ing residues 392-610,30 also was revealed to contain an FXIIIa
incorporation site. As we can see it in some amino acid substitu-
tions not associated with the  cross-linking site, such as Caracas
II31 (ASer434AsnN-glycosylated), Tokyo V32 (Ala327thr), and
Thr312Ala polymorphism,33 the amount of -cross-linking is
proportionate to fiber thickness. Therefore, in addition to the
mutation itself, we think that the fact that thicker fibers tend to have
more -chain cross-links28 also can account for the difference in
the amount of -chain cross-linking between normal and heterozy-
gous Seoul II fibrin clots. Heterozygous Seoul II fibrin -chains
were still present as monomers after 90 minutes of incubation by
the reducing SDS-PAGE (data not shown). Considering the muta-
tional site and the SDS-PAGE analysis, -cross-linking of Seoul II
fibrinogen is thought to be impaired.
Interestingly, the -chains of the heterozygous Seoul II fibrin
formed - dimers more rapidly than normal fibrin in 1 to 5
minutes when treated with factor XIIIa. We think this finding
suggests that protofibril elongation is predominant over lateral
aggregation in the early process of fibrin assembly for the
heterozygous Seoul II fibrin, possibly due to impaired lateral
aggregation. Further studies are necessary to clarify this finding.
In fibrinolysis profiles, where turbidity was continuously monitored
from the beginning of fibrin formation to fibrinolysis, peak absorbance
in heterozygous Seoul II fibrin clots occurred 40 seconds later than in
normal clots (Figure 5), suggesting delayed fibrinolysis in Seoul II fibrin
clots. This finding suggests that the Seoul II fibrin mutation might have
precipitated thrombotic processes, although it should be noted that the
subject already had risk factors for thrombosis, including hypertension
and a history of heavy smoking. The mutation might also have induced a
conformational change that alters the t-PAand plasminogen-binding site
in residues 392-61034 of C-domain, making it difficult to access.
Studies about stiffness, compaction, and permeation will be required to
make the effect of the Seoul II mutation on fibrinolysis clear.
As for the Seoul II mutation, molecular modeling would be
helpful to confirm conformational changes in the C domain.
However, numerous attempts to crystallize preparations for the C
domain have not succeeded because the region is highly mobile and
there is little evidence for features such as  helices or  sheets.35
The study of a homozygous Seoul II mutation would be helpful in
understanding the impact of the mutation on disease but, unfortu-
nately, all family members were not available to study the
transmission of the mutation. In conclusion, this report describes a
new fibrinogen variant characterized by an amino acid substitution
(AGln328Pro) in a site involved in -cross-linking. Seoul II fibrin
shows a decrease in final turbidity on polymerization and impaired
fibrin -chain cross-linking. This characterization of fibrinogen
Seoul II describes its influence on fibrin assembly and cross-linking.
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